US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1 -Mutated Advanced or Metastatic Breast Cancer.
Mirat ShahHima LingamXin GaoHaley GittlemanMallorie H FieroDanielle KrolNikolett BielTiffany K RicksWentao FuSalaheldin HamedFang LiJillian Jielin SunJianghong FanRobert N SchuckManuela GrimsteinLiuya TangShyam KalavarAbdelrahmman AbukhdeirAnand PathakSoma GhoshIlynn BulataoAmy TilleyWilliam F PierceBronwyn D MixterShenghui TangRichard PazdurPaul KluetzLaleh Amiri-KordestaniPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
mutations.